Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Prof. Herbert Loong, Scientific Committee Track Co-Chair(Developmental & precision medicine), presents highlights of the upcoming edition of this congress, focusing on a wide range of oncology topics
Discover how to implement the ESMO Guidelines in real-world clinical scenarios and contribute to a richer learning experience by submitting your questions to the experts.
Shape the future of cancer drug development and be part of this unique forum gathering key actors in the field
Your research has the potential to shape the future of breast cancer care
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Findings from the NICHE-3 study
ESMO welcomes the outcome of the hearings for Olivér Várhelyi, Commissioner-designate for Health and Animal Welfare, where several topics relevant for the oncology community were addressed in a positive or at least promising way
ESMO continues with its efforts to fight the tobacco epidemic and to achieve the ambitious goal of creating the Tobacco-Free Generation, set in the Europe’s Beating Cancer Plan (EBCP)
Findings from the BELLINI study
Evidence for efficacy is based on the results from the INAVO120 study
New indications concern patients with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and oesophageal squamous cell carcinoma
Findings from the NIAGARA study
Findings from the COMPASSION-16 study
In a rapidly evolving landscape, this updated CPG covers new recommendations for neoadjuvant therapy in stage III melanoma, as well as options for advanced disease based on (neo)adjuvant treatment, disease and patient characteristics
Findings from the NICHE-3 study
Findings from the BELLINI study
Evidence for efficacy is based on the results from the INAVO120 study
New indications concern patients with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and oesophageal squamous cell carcinoma
Findings from the NIAGARA study
Findings from the COMPASSION-16 study
Final invasive disease-free survival results from the NATALEE study
FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device
It is intended for the intraperitoneal treatment of malignant ascites
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand
The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers
The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world
Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment
ESMO welcomes the outcome of the hearings for Olivér Várhelyi, Commissioner-designate for Health and Animal Welfare, where several topics relevant for the oncology community were addressed in a positive or at least promising way
The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works
Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)
The recipients of the 2024 ESMO Society Awards have been announced today by ESMO
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
The deployment of artificial intelligence could lead to substantial advances in cancer care, but collaborative efforts are needed to increase trust among end users
Some initiatives show that collection and distribution of unused medicines can help tackle drug waste, with a potential impact on emissions associated to oncology therapies
Findings from complex statistical modelling can form the basis for easy-to-use precision diagnostic and risk-stratification tools to help inform management decisions
Whole-genome sequencing and single-cell sequencing can provide valuable insights not only in the identification of new therapy targets, but also to assess minimal residual disease and overcome treatment resistance
Newly-presented studies highlight that insights into cancer can also be unlocked from circulating tumour cells, exosomal microRNA and cell-free RNA
Among the presented findings, a potential role for ESR1 gene fusions was observed
Advances in spatial transcriptomics could provide novel opportunities for early detection, metastasis prediction and identification of actionable targets
Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Republic of Singapore
Republic of Singapore
Republic of Singapore
Republic of Singapore
Switzerland
Switzerland
South Africa
South Africa
Switzerland
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
